PDS Biotechnology Newsroom

'PDS Biotech's Survival Benefit Is Absurdly Overstated' - By Adam Feuerstein/ STAT News

This is the online edition of Adam's Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.Hello, friends! I'm in Sa

BenzingaMay 16 11:03 ET

PDS Biotechnology | 10-Q: Quarterly report

SEC announcementMay 15 17:22 ET · Announcements

Buy Rating Affirmed for PDS Biotechnology on Strong Financials and Promising Clinical Pipeline

TipRanksMay 15 09:45 ET

Express News | PDS Biotechnology Q1 2024 GAAP EPS $(0.30) Beats $(0.37) Estimate, Cash $66.6M

BenzingaMay 15 08:04 ET

Express News | PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

ReutersMay 15 08:00 ET

PDS Biotechnology 1Q Research and Development Expenses $6.7M >PDSB

PDS Biotechnology 1Q Research and Development Expenses $6.7M >PDSB

Dow JonesMay 15 08:00 ET

PDS Biotechnology 1Q Loss/Shr 30c >PDSB

PDS Biotechnology 1Q Loss/Shr 30c >PDSB

Dow JonesMay 15 08:00 ET

Express News | PDS Biotechnology Q1 EPS USD -0.3 Vs. Ibes Estimate USD -0.37

ReutersMay 15 08:00 ET

Express News | PDS Biotechnology Q1 Net Income USD -10.6 Million

ReutersMay 15 08:00 ET

PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study

PDS Biotechnology (PDSB) said late Thursday its experimental therapy to treat a type of head and neck cancer in combination with Merck's Keytruda met the primary study endpoints in a phase 2 clinical

MT NewswiresMay 10 05:49 ET

Express News | PDS Biotech's VERSATILE-002 Phase 2 Clinical Trial Met Primary Study Endpoints

BenzingaMay 9 18:09 ET

Express News | PDS Biotechnology Corp: Plans to Initiate a Pivotal Clinical Trial in 2024 to Advance Its Lead Program in Advanced Head and Neck Squamous Cell Cancers

ReutersMay 9 17:47 ET

Express News | PDS Biotech Versatile-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic Hpv16-Positive Head and Neck Cancer

ReutersMay 9 17:46 ET

Express News | HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

BenzingaMay 9 15:35 ET

Express News | Cantor Fitzgerald Reiterates Overweight on PDS Biotechnology

BenzingaMay 9 11:12 ET

PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets

GlobeNewswireMay 9 08:00 ET

Buy Rating Affirmed on PDS Biotechnology's Promising HNSCC Treatment Developments

TipRanksMay 9 06:38 ET

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets

GlobeNewswireMay 7 08:00 ET

PDS Biotechnology Announces Details of Virtual KOL Event

PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets

GlobeNewswireMay 3 08:00 ET

PDS Biotech: Toutain's Appointment Effective From May 1 >PDSB

PDS Biotech: Toutain's Appointment Effective From May 1 >PDSB

Dow JonesMay 2 08:01 ET